Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 6 of 6 results for zanamivir

  1. Amantadine, oseltamivir and zanamivir for the treatment of influenza (TA168)

    Evidence-based recommendations on amantadine (Lysovir), oseltamivir (Tamiflu) and zanamivir (Relenza) for treating influenza in children and adults.

    Technology appraisal guidance
    Published
    25 February 2009
    View recommendations

    Sections for TA168

  2. Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza (TA158)

    Evidence-based recommendations on oseltamivir (Tamiflu), amantadine (Lysovir or Symmetrel) or zanamivir (Relenza) for preventing flu.

    Technology appraisal guidance
    Published
    24 September 2008
    View recommendations

    Sections for TA158

  3. History of NICE

    published our first piece of guidance: a rapid assessment of flu product zanamivir. First public board meeting Register to attend a...

  4. Intravenous zanamivir for treating influenza in hospital [ID1196]

    Discontinued [GID-TA10298]

    Technology appraisal guidance
    Discontinued

  5. Flu treatment - zanamivir, amantadine and oseltamivir (TA58)

    This guidance has been updated and replaced by NICE technology appraisal guidance 168.

    Technology appraisal guidance
    Published
    26 February 2003

  6. Zanamivir for the treatment of influenza in adults (TA15)

    This guidance has been replaced by NICE technology appraisal guidance 58 [Replaced by NICE technology appraisal guidance 168].

    Technology appraisal guidance
    Published
    27 November 2000